Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: egaptivon pegol, caplacizumab, von willebrand factor human +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 13,815 | 0.70 |
| pathways Reactome | 25 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 9852
Sealed predictions
- VWF in dopamine neurons, braak-0.39 (p 0.304) → -0.05 (p 0.893)receipt 9860
Swarm cases
receipt 9860: VWF in dopamine neurons, braak
- power
- full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.120, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VWF in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts